Kidney Diseases

MorphoSys AG (NASDAQ: MOR) presented interim results from the M-PLACE Phase 1b/2a study with felzartamab at the 2021 Annual Meeting of the American Society of Nephrology (ASN). Felzartamab is a fully human IgG1 monoclonal anti-CD38 antibody that can potentially deplete CD38-positive...

Novartis AG (NYSE: NVS) has announced Phase 2 trial data of iptacopan, a selective factor B inhibitor, in patients with C3 glomerulopathy (C3G). In C3G, an overly-active alternative complement pathway causes deposits of C3 protein to build up in blood vessels that filter waste and remove...

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) has announced top-line results from its PHYOX4 study of nedosiran for primary hyperoxaluria type 3 (PH3).  Related: Why Is Dicerna Stock Getting Slammed Today? Nedosiran demonstrated safety and tolerability results consistent with...

The FDA has signed off Caladrius Bioscience Inc's (NASDAQ: CLBS) investigational new drug application for the study of CLBS201 for the treatment of diabetic kidney disease ("DKD"). The company plans to initiate a Phase 1/2 proof-of-concept study of CLBS201 within the...

Novartis AG (NYSE: NVS) announced data from Phase 2 trial evaluating iptacopan (LNP023) in rare kidney disease IgA nephropathy (IgAN). Data were presented at the 58th ERA-EDTA Congress. IgA nephropathy, also known as Berger's disease, occurs when an antibody called immunoglobulin A (IgA)...

Following the pre-NDA meeting, the FDA has asked Travere Therapeutics Inc (NASDAQ: TVTX) to submit additional data for the sparsentan program in focal segmental glomerulosclerosis (FSGS), characterized by scarring (sclerosis) in the kidney. The agency indicated that the...

Shares of Anthera Pharmaceuticals Inc (NASDAQ: ANTH), a nano-cap bio-pharmaceutical company that focuses on developing and commercializing products to treat serious diseases, soared higher by more than 30 percent on Wednesday. Anthera announced on Tuesday positive data from its Phase 2 BRIGHT-...